Vericel (VCEL) Net Cash Flow (2010 - 2026)
Vericel (VCEL) posted Net Cash Flow of $16.1 million for Q2 2026, up 74.54% sequentially from $9.2 million in Q1 2026, and up 1842.32% YoY from $827000.0 in Q2 2025.
Vericel (VCEL) Net Cash Flow (2010 - 2026) Analysis & Trends
Vericel has reported Net Cash Flow for 17 years, with the latest figure at $16.1 million in Q2 2026.
- Quarterly Net Cash Flow rose 1842.32% year-over-year to $16.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $44.8 million (up 858.23% YoY) and the FY2025 annual result came in at $15.0 million, up 927.9% from the prior year.
- Net Cash Flow advanced to $16.1 million in Q2 2026 per VCEL's latest filing, from $9.2 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $19.9 million in Q3 2025 and troughed at -$16.1 million in Q1 2024.
- A 5-year average of $3.2 million and a median of $3.1 million in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Net Cash Flow soared 2174.18% in 2023, then plunged 249.75% in 2024.
- Over 5 years, Net Cash Flow stood at -$14.1 million in 2022, then jumped by 123.36% to $3.3 million in 2023, then surged by 344.75% to $14.7 million in 2024, then slumped by 102.12% to -$311000.0 in 2025, then soared by 5264.95% to $16.1 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $16.1 million, $9.2 million, and -$311000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 16.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.06 Mn |
| Jun 30, 2026 | 16.06 Mn |
| Mar 31, 2026 | 9.20 Mn |
| Mar 31, 2026 | 9.20 Mn |
| Dec 31, 2025 | -311,000.00 |
| Dec 31, 2025 | -311,000.00 |
| Sep 30, 2025 | 19.87 Mn |
| Sep 30, 2025 | 19.87 Mn |
| Jun 30, 2025 | 827,000.00 |
| Jun 30, 2025 | 827,000.00 |
| Mar 31, 2025 | -5.34 Mn |
| Mar 31, 2025 | -5.34 Mn |
| Dec 31, 2024 | 14.70 Mn |
| Dec 31, 2024 | 14.70 Mn |
| Sep 30, 2024 | -5.50 Mn |
| Sep 30, 2024 | -5.50 Mn |
| Jun 30, 2024 | 5.11 Mn |
| Jun 30, 2024 | 5.11 Mn |
| Mar 31, 2024 | -16.12 Mn |
| Mar 31, 2024 | -16.12 Mn |